Having trouble accessing articles? Reset your cache.

Fenretinide: Additional Phase IIb data

Additional data from a 24-month, double-blind Phase IIb trial in 246 patients showed that 100 and 300 mg once-daily oral fenretinide led to median GA lesion growth

Read the full 277 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE